These findings largely align with whats been seen with tirzepatide and other GLP-1based medications, including small risks of pancreatitis and gallbladder issues, dose-related gastrointestinal side effects, and discontinuation due to tolerability
With the loss of exclusivity, several companies, including Sandoz, Apotex, Teva, Taro, Vimy Pharma, Hims & Hers, and Biocon, have filed applications to launch generic versions of semaglutide, but they are pending Health Canadas regulatory approval
Tracey's Transformation "I lost 19 pounds with the DNM Semaglutide program and feel like a new person." Ernie's Experience "Semaglutide helped me lose weight and ease my back pain
At 1 mg/mL, 100 units equals just 1 mg, a moderate dose within normal protocols